Pfizer PFE Comirnaty — Remaining performance obligation
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pfizer in its filing.
Tagged under the XBRL concept us-gaap:RevenueRemainingPerformanceObligation.
The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pfizer's comirnaty — remaining performance obligation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Pfizer's comirnaty — remaining performance obligation?
- Pfizer (PFE) reported comirnaty — remaining performance obligation of $2.1B in Q1 2026.
- How has Pfizer's comirnaty — remaining performance obligation changed year-over-year?
- Pfizer's comirnaty — remaining performance obligation decreased by 30.0% year-over-year, from $3B to $2.1B.
- What does comirnaty — remaining performance obligation mean?
- This metric represents the total transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the reporting date. It provides visibility into future revenue that is under contract but has not yet been recognized. It is a key indicator of the company's revenue backlog and future sales predictability.